Table 1 Reported global annual product sales by calendar year for selected medicines according to company annual reports (2004–2017) (in million USD)a
Year | Sovaldi® (sofosbuvir) Gilead [47] | Herceptin® (trastuzumab) Roche & Genentech [48] | Gleevec/Glivec® (imatinib) Novartis [49] |
|---|---|---|---|
2004 | N/A | 1162 | 1634 |
2005 | N/A | 1717 | 2170 |
2006 | N/A | 3142 | 2554 |
2007 | N/A | 4027 | 3050 |
2008 | N/A | 4736 | 3944 |
2009 | N/A | 4845 | 3944 |
2010 | N/A | 5212 | 4265 |
2011 | N/A | 5936 | 4659 |
2012 | N/A | 6301 | 4675 |
2013 | 139 | 6565 | 4693 |
2014 | 10,283 | 6840 | 1237 |
2015 | 5276 | 6800 | 1219 |
2016 | 4001 | 6918 | 3323 |
2017 | 964 | 7154 | 1943 |
Total | 20,663 | 34,277 | 43,310 |